Date: 2016-03-23
Type of information: Initiation of development program
phase: 1
Announcement: initiation of development program
Company: Active Biotech (Sweden)
Product: tasquinimod
Action
mechanism: immunomodulator/immunotherapy product. TASQ (tasquinimod, ABR-215050) binds to a molecule called S100A9 which is expressed in the white blood cells involved in the regulation of immune responses. S100A9 interacts with two known pro-inflammatory receptors (Toll like receptor 4 (TLR4) and receptor of advanced glycation end products (RAGE)) and this interaction is inhibited by TASQ (Björk et al PLoS Biology, April 2009).
Disease: multiple myeloma
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On March 23, 2016, Active Biotech announces that a patent application for the treatment of multiple myeloma with the company's compound tasquinimod, together with an international search report, will be public within short on WIPO's (World Intellectual Property Organization) web site (application WO 2016/042112). A preclinical program has been already performed and very good results were achieved in models for multiple myeloma. During 2016 orphan drug status applications for tasquinimod treatment of multiple myeloma are planned to be submitted to authorities in the EU and USA.
